Samia Mora, MD, MHS
Associate Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women’s Hospital
Dr. Mora is a cardiovascular medicine specialist at the Brigham and Women’s Hospital, where she is the Director of the Center for Lipid Metabolomics. She has joint appointments in the Divisions of Preventive Medicine, Cardiovascular Medicine, and Women’s Health. Dr. Mora received her undergraduate degree from Harvard University, and her medical degree from Harvard Medical School. She completed an internal medicine residency at Massachusetts General Hospital and a cardiovascular disease fellowship at The Johns Hopkins Hospital, where she also obtained a Masters in Health Science (Epidemiology) from the Johns Hopkins Bloomberg School of Public Health. She is board certified in cardiovascular disease and echocardiography, and is a Fellow of the American Heart Association, American College of Cardiology, and American Society of Echocardiography. She also serves on the Editorial Boards of JAMA Internal Medicine and Atherosclerosis. Dr. Mora’s clinical interests include cardiovascular prevention, lipids, modifiable risk factors, and women’s health. The author of over 150 peer-reviewed publications, Dr. Mora’s research focuses on risk factors and prevention of cardiovascular disease. She is actively involved with several randomized clinical trials and observational studies, having served on the Endpoints Committee of the Women’s Health Study, the Clinical Coordinating Committee of the JUPITER trial, the Steering Committee of the VITAminD and OmegA-3 Trial (VITAL), and the Harvard Investigator on the Gulf Population Risks and Epidemiology of Vascular Events and Treatment (Gulf PREVENT) study. Dr. Mora recently co-developed (with Dr. Manson and Mr. Ames) the free Aspirin-Guide mobile app for aspirin in primary prevention of cardiovascular disease (available for iPhone, iPad, Android, and on the web on www.aspiringuide.com). Dr. Mora is an Elected Member of the Association for University Cardiologists and the American Society for Clinical Investigation.
AB: Harvard University
MD: Harvard Medical School
MHS: Johns Hopkins Bloomburg School of Public Health
- Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation.2013;128(11):1189-97.
- Mora S, Manson JE. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. JAMA Intern Med. 2016;176(8):1195-204.
- Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, et al. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2017;135(25):2494-504.
- Mora S, Wenger NK, Cook NR, Liu J, Howard BV, Limacher MC, et al. Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women’s Health Initiative. JAMA Intern Med. 2018;178(9):1231-40.
- Mora S, Chang CL, Moorthy MV, Sever PS. Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm. JAMA Intern Med. 2019;179(7):898-905.